Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: Clinical outcome, microbiology and pharmacokinetics

Journal of Antimicrobial Chemotherapy

Volumn 40, Issue 1, 1997, Pages 125-133

  Vinks, Alexander A T M M ^a   Brimicombe, Roland W ^b   Heijerman, Harry G M ^b   Bakker, Wim ^b  

^a Central Hospital Pharmacy   (Netherlands)

^b LEYENBURG HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CYSTIC FIBROSIS; DRUG CLEARANCE; DRUG EFFICACY; FEMALE; HOME CARE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG INFECTION; MALE; PROSPECTIVE STUDY; PSEUDOMONAS AERUGINOSA;

ADOLESCENT; ADULT; CEFTAZIDIME; CYSTIC FIBROSIS; FEMALE; HOME INFUSION THERAPY; HUMANS; INFUSIONS, INTRAVENOUS; LUNG DISEASES; MALE; MIDDLE AGED; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; SPUTUM; TREATMENT OUTCOME;

EID: 0030797241     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/40.1.125     Document Type: Article

References (47)

1. British Paediatric Association Working Party on Cystic Fibrosis. (1988). Cystic fibrosis in the United Kingdom 1977-85: an improving picture. British Medical Journal 297, 1599-602.
2. Fiel, S. B. (1993). Clinical management of pulmonary disease in cystic fibrosis. Lancet 341, 1070-4.
3. Marks, M. I. (1981). The pathogenesis and treatment of pulmonary infections in patients with cystic fibrosis. Journal of Pediatrics 98, 173-9.
4. Rucker, R. W. & Harrison, G. M. (1974). Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 54, 358-60.
5. Donati, M. A., Guenette, G. & Auerbach, H. (1987). Prospective controlled study of home and hospital therapy of cystic fibrosis pulmonary disease. Journal of Pediatrics 111, 28-33.
6. Martinez, M. A., Votoroubek, W., Hoefle, K. & Lemen, R. J. (1987). Efficacy of respiratory home care versus in-patient care of cystic fibrosis patients. American Review of Respiratory Disease 135, Suppl. A, 194.
7. Kane, R. E., Jennison, K., Wood, C., Black, P. G. & Herbst, J. J. (1988). Cost savings and economic considerations using home intravenous antibiotic therapy for cystic fibrosis. Pediatric Pulmonology 4, 84-9.
8. Kuzemko, J. A., Williams, K. J. & Bigley, J. (1986). Home intravenous treatment of pulmonary infections in cystic fibrosis. In Cystic Fibrosis in Children, Practical and Legal Aspects of Intravenous Antibiotic Administration at Home (David, T. J., Ed.), pp. 29-37. Excerpta Medica, Amsterdam.
9. Kuzemko, J. A. (1988). Home treatment of pulmonary infection in cystic fibrosis. Chest 94, Suppl. 2, 162S-6S.
10. Davis, S., Mather, F., Tankershy, P., Waring, W. & The MCH Home IV Antibiotic Study Group. (1990). A randomized trial of home intravenous antibiotic treatment (HIVAT) in cystic fibrosis (CF): short-term safety and efficacy. Pediatric Pulmonology 9, Suppl. 5, Abstract 207, p. 245.
11. Strandvik, B., Hjelte, L., Malmborg, A. S. & Widén, B. (1992). Home intravenous antibiotic treatment of patients with cystic fibrosis. Acta Paediatrica 81, 340-4.
12. Pond, M. N., Newport, M., Joanes, D. & Conway, S. P. (1994). Home versus hospital intravenous antibiotic therapy in the treatment of young adults with cystic fibrosis. European Respiratory Journal 7, 1640-4.
13. Permin, H., Koch, C., Høiby, N., Christensen, H. O., FritsMoller, A. F. & Moller, S. (1983). Ceftazidime treatment of chronic Pseudomonas aeruginosa respiratory tract infection in cystic fibrosis. Journal of Antimicrobial Chemotherapy 12, Suppl. A, 313-23.
14. Gold, R., Overmeyer, A., Knie, B., Fleming, P. C. & Levinson, H. (1985). Controlled trial of ceftazidime vs. ticarcillin and tobramycin in the treatment of acute respiratory exacerbations in patients with cystic fibrosis. Pediatric Infectious Disease 4, 172-7.
15. Stenvang Pedersen, S., Pressler, T., Pedersen, M., Høiby, N., Friis-Møller, A. & Koch, C. (1986). Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis. Scandinavian Journal of Infectious Diseases 18, 133-7.
16. Padoan, R., Cambisano, W., Constantini, D., Crossignani, R. M., Danza, M. L., Trezzi, G. et al. (1987). Ceftazidime monotherapy vs combined therapy in Pseudomonas pulmonary infections in cystic fibrosis. Pediatric Infectious Disease Journal 6, 648-53.
17. LeBel, M. & Spino, M. (1998). Pulse dosing versus continuous infusion of antibiotics. Pharmacokinetic-pharmacodynamic considerations. Clinical Pharmacokinetics 14, 71-95.
18. Craig, W. A. & Ebert, S. C. (1992). Continuous infusion of β- lactam antibiotics. Antimicrobial Agents and Chemotherapy 36, 2577-83.
19. Mouton, J. W. & den Hollander, J. G. (1994). Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrobial Agents and Chemotherapy 38, 931-6.
20. David, T. J. & Devlin, J. (1989). Continuous infusion of ceftazidime in cystic fibrosis. Lancet ii, 1454-5.
21. Kuzemko, J. & Crawford, C. (1989). Continuous infusion of ceftazidime in cystic fibrosis. Lancet i, 385.
22. Mouton, J. W. & Vinks, A. A. T. M. M. (1996). Is continuous infusion of β-lactam antibiotics worthwhile? - efficacy and pharma- cokinetic considerations. Journal of Antimicrobial Chemotherapy 38, 5-15.
23. Smith, A. L. (1986). Antibiotic therapy in cystic fibrosis; evaluation of clinical trials. Journal of Pediatrics 108, 866-70.
24. Levy, J. (1988). Antibiotic therapy in cystic fibrosis. Evaluation of efficacy. Chest 94, Suppl. 2, 150S-6S.
25. Stiles, M. L., Tu, Y.-H. & Allen, L. V. (1989). Stability of cefazolin sodium, cefoxitin sodium, ceftazidime, and penicillin-G sodium in portable pump reservoirs. American Journal of Hospital Pharmacy 46, 1408-12.
26. Dutch Working Party on Guidelines for Susceptibility Testing. (1990). Standardisation of Susceptibility Tests, Second Supplement. Bilthoven, The Netherlands.
27. Vinks, A. A. T. M. M., Touw, D. J., Heijerman, H. G. M., Danhof, M., de Leede, G. P. J. & Bakker, W. (1994). Pharmacokinetics of ceftazidime in adult cystic fibrosis patients during continuous infusion and ambulatory treatment at home. Therapeutic Drug Monitoring 16, 341-8.
28. Van der Vaart, F. J. (1992). Guidelines for validation of analytical procedures in pharmaceutical and biopharmaceutical analysis. Pharmaceutisch Weekblad 46, 1229-35.
29. Proost, J. H. & Meijer, D. K. F. (1992). MW/PHARM, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Computers in Biology and Medicine 22, 155-63.
30. Hallynck, T. H., Soep, H. H., Thomis, J. A., Boelaert, J., Daneels, R. & Dettli, L. (1981). Should clearance be normalised to body surface area or to lean body mass? British Journal of Clinical Pharmacology 11, 523-6.
31. Vinks, A. A. T. M. M., Heijerman, H. G. M., de Jonge, P. & Bakker, W. (1993). Photosensitivity due to ambulatory intravenous ceftazidime in cystic fibrosis patient. Lancet 341, 1221-2.
32. Byl, B., Baran, D., Herchuelz, A., Roucloux, I., Lambert, C., van der Auwera, P. et al. (1992). Sputum penetration of a single daily dose of amikacin and of a continuous infusion of ceftazidime in cystic fibrosis. In Program and Abstracts of the Thirty-Second Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheim, CA, 1992. Abstract 209, p. 145. American Society for Microbiology, Washington, DC.
33. Mouton, J. W., Horrevorts, A. M., Overbeek, S. E., Kerrebijn, K. F. & Michel, M. F. (1992). Pharmacokinetics of ceftazidime during continuous and intermittent infusion in adult cystic fibrosis patients. In Program and Abstracts of the XIth International Cystic Fibrosis Congress, Dublin, 1992. Abstract TP16. Cystic Fibrosis Association, Dublin.
34. Nicolau, D. P., Nightingale, C. H., Banevicius, M. A., Fu, Q. & Quintiliani, R. (1996). Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrobial Agents and Chemotherapy 40, 61-4.
35. Benko, A. S., Cappelletty, D. M., Kruse, J. A. & Rybak, M. J. (1996). Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected Gram-negative infections. Antimicrobial Agents and Chemotherapy 40, 691-5.
36. Bakker, W., Vinks, A. A. T. M. M., Mouton, J. W., de Jonge, P., Verzijl, J. G. & Heijerman, H. G. M. (1993). Continuous infusion treatment at home of respiratory tract infections with ceftazidime using a portable pump in cystic fibrosis patients: a multi-centre study. Nederlands Tijdschrift voor Geneeskunde 137, 2486-91.
37. Byrne, S., Maddison, J., Connor, P., Doughty, I., Dodd, M., Jenney, M. et al. (1995). Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. infections in cystic fibrosis patients. Journal of Antimicrobial Chemotherapy 36, Suppl. A, 135-43.
38. Watkins, J., Francis, J. & Kuzemko, J. A. (1988). Does monotherapy of pulmonary infections lead to early development of resistant strains of Pseudomonas aeruginosa? Scandinavian Journal of Gastroenterology, Suppl. 143, 81-5.
39. Hodson, M. E., Roberts, C. M., Butland, R. J. A., Smith, M. J. & Batten J. C. (1987). Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa in adults with cystic fibrosis. Lancet i, 235-7.
40. Dalzell, A. M., Sunderland, D., Hart, C. A. & Heaf, D. P. (1991). Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces. Thorax 46, 239-41.
41. Steru, D., Bergogne-Bérézin, E. & Lenoir, G. (1984). Blood and sputa levels of ceftazidime in cystic fibrosis patients. In Cystic Fibrosis Horizons: Proceedings of the 9th International Cystic Fibrosis Congress, Brighton, 1984 (Lawson, D., Ed.), p. 281. Wiley, Chichester.
42. Turner, A., Pedler, S. J., Carswell, F., Spencer, G. R. & Speller, D. C. E. (1984). Serum and sputum concentrations of ceftazidime in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy 14, 521-7.
43. Gordon, C. A., Hodges, N. A. & Marriott, C. (1988). Antibiotic interaction and diffusion through alginate and exopolysaccharide of cystic fibrosis-derived Pseudomonas aeruginosa. Journal of Antimicrobial Chemotherapy 22, 667-74.
44. Bolister, N., Basker, M., Hodges, N. A. & Marriott, C. (1991). The diffusion of β-lactam antibiotics through mixed gels of cystic fibrosis-derived mucin and Pseudomonas aeruginosa alginate. Journal of Antimicrobial Chemotherapy 27, 285-93.
45. Levy, J. (1986). Antibiotic activity in sputum. Journal of Pediatrics 108, 841-6.
46. Sörgel, F., Stephan, U., Wiesemann, H. G., Gottschalk, B., Stehr, C., Rey, M. et al. (1987). High dose treatment with antibiotics in cystic fibrosis. A reappraisal with special reference to the pharmacokinetics of beta-lactams and new fluoroquinolones in adult CF patients. Infection 15 , 385-96.
47. Lindsay, C. A. & Bosso, J. A. (1993). Optimisation of antibiotic therapy in cystic fibrosis patients. Pharmacokinetic considerations. Clinical Pharmacokinetics 24, 496-506.